High expression of SIGLEC7 may promote M2-type macrophage polarization leading to adverse prognosis in glioma patients
Open Access
- 15 August 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1411072
Abstract
Introduction: Gliomas are the most common primary intracranial tumors, known for their high invasiveness and destructiveness. Sialic acid-binding immunoglobulin-like lectin 7 (SIGLEC7) is present in various immune cells, especially macrophages, and significantly affects immune homeostasis and cancer cell response. However, research on the role and prognostic impact of SIGLEC7 in glioma patients is currently limited.Methods: We utilized transcriptomic data from 702 glioma patients in The Cancer Genome Atlas (TCGA) and 693 glioma patients in the Chinese Glioma Genome Atlas (CGGA), along with clinical samples we collected, to comprehensively investigate the impact of SIGLEC7 on glioma expression patterns, biological functions, and prognostic value. We focused on its role in glioma-related immune responses and immune cell infiltration and analyzed its expression at the single-cell level. Finally, we validated the role of SIGLEC7 in gliomas through tissue and cell experiments.Results: SIGLEC7 expression was significantly increased in glioma patients with malignant characteristics. Survival analysis indicated that glioma patients with high SIGLEC7 expression had significantly lower survival rates. Gene function analysis revealed that SIGLEC7 is primarily involved in immune and inflammatory responses and is strongly negatively correlated with tumor-associated immune regulation. Additionally, the expression of most immune checkpoints was positively correlated with SIGLEC7, and immune cell infiltration analysis clearly demonstrated a significant positive correlation between SIGLEC7 expression and M2 macrophage infiltration levels. Single-cell analysis, along with tissue and cell experiments, confirmed that SIGLEC7 enhances macrophage polarization towards the M2 phenotype, thereby promoting glioma invasiveness through the immunosuppressive effects of M2 macrophages. Cox regression analysis and the establishment of survival prediction models indicated that high SIGLEC7 expression is an unfavorable prognostic factor for glioma patients.Discussion: High SIGLEC7 expression predicts poor prognosis in glioma patients and is closely associated with M2 macrophages in the tumor environment. In the future, SIGLEC7 may become a promising target for glioma immunotherapy.Keywords
This publication has 40 references indexed in Scilit:
- Autophagy-driven regulation of cisplatin response in human cancers: Exploring molecular and cell death dynamicsCancer Letters, 2024
- Wnt/β-catenin-driven EMT regulation in human cancersCellular and Molecular Life Sciences, 2024
- Glioma: molecular signature and crossroads with tumor microenvironmentCancer and Metastasis Reviews, 2021
- Expression profiling of immune inhibitory Siglecs and their ligands in patients with gliomaCancer Immunology, Immunotherapy, 2019
- Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain TumorCell, 2018
- Glioma epigenetics: From subclassification to novel treatment optionsSeminars in Cancer Biology, 2018
- THP-1 cell line: An in vitro cell model for immune modulation approachInternational Immunopharmacology, 2014
- The role of targeted therapies in the management of progressive glioblastomaJournal of Neuro-Oncology, 2014
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cellsImmunobiology, 2004